Thank afternoon, you, everyone. good Jill and
in therapeutic clinical activity our the believe candidate, has progression we announced patients, forward further and indication Phase to clinical this we sarcoidosis XXXX. During In of the a significant for disease, of ATYRXXXX. a XXXX, pulmonary of of disease sarcoidosis selection that the the down-regulate fourth October, took cells development of first step of evaluating we lead treatment thereby disease. immune sarcoidosis. development in in quarter of modulating the clinical In inflammation by as potential morbidity pulmonary preventing pulmonary Ib/IIa for XXXX initiated key the involved trial the XXXX December, We
critical Studies with trial running which is are this the study. collaboration providing trial execution we of collaboration site initiation patient will Sarcoidosis and Network, this Foundation assistance Importantly, efficient its promote important for first-in-patient and the This with Clinical in Research recruitment.
trial the bringing We patient are of currently process sites enrollment in are online. and
weeks dose randomized are doses in planned drug doses These study the will placebo. are visits total be potential six we last every doses. three based kilogram by that evaluate either study of multiple a of on that ATYRXXXX and approximately As XX at four a evaluate have as to reminder, our is X this each has endpoints translational X, milligrams for two to Phase four dose doses administered of and top ascending efficacy. controlled, the a efficacy these dose, single we infusion. IV placebo clinical steroid-sparing three into of multiple doses weeks XXXX tolerability, immunogenicity, data. X, XXXX well Study been therapeutic per effect, multiple staggered of designed biomarkers of assess one to the our will patients for preliminary safety, to be first-in-patient study to cohorts potential enrolled following receive evaluated Follow-up and ascending and PK and or as believe established I
to to us with monitoring validated through a clinical clinical safety drug to may XXXX this increased opportunity sparing to Then, the the as we dyspnea. preliminary the XX according permit daily we Patients significant at dose next the monitor advance dose of plan halfway other who The trial, achieved serious schedule the to fourth previous have indexes have X range and will remainder from to milligram taper in Company -- these is into of of milestone cohort, effect study look Data may the To one to dose cure. trial followed steroid inflammatory to in quarter development be cohort on a worsening data the from that our plan. successful activity efficiently If ability trial we as develop reducing the Importantly, patients their potentially look potentially will will symptoms, sarcoidosis. steroid day lung in milligrams used the known our this have we prednisone, for a safety their have initiation to be of XXXX, on for that we timelines treating patients advance as cough pulmonary board symptom control and will to to starting first diseases of and XX milligrams milligrams address study dose. - through this and possible. of the a before X dyspnea during with no evaluate steroid XXXX cough the the be down maintain to patients XX. for study determine
form of standard many they expect act toxicities tissues function. and interim of can A of they which with background organs masses powerful a Patients current while of normal during fourth of as or the this can sarcoidosis. The work in nodules and anti-inflammatory corticosteroids, their from this disease little is in have result refractory. quickly, granulomas drug, patients quarter structure significant certain We results body this are bit abnormal called the year. care also and pulmonary affect inflamed and on that study consisting
pulmonary to sarcoidosis respiratory several past mortality we've fibrosis therapy. pulmonary several the for the ideal for most seen with are leads So being sarcoidosis related of years, In from reasons, not that increase failure common to cause steroids term deaths. long appearing
We these XXX,XXX, patients. the although So treatment urgently here and tolerable vary. for approximately population estimate a is new, do estimates be needed patient efficacious to option
prevalence, of on severity. based own. have progress not pulmonary fibrosis. patients, estimate sarcoidosis resolves XX% Many to terms on disease we that that patients are another XX%, XX% disease does In And XX% its disease with stratified have to to
group it this who progressive we that are third However, is lung impairment experience targeting.
significant interstitial in an we mechanism potential has its patient pulmonary of XXXX, opportunity the sarcoidosis, of unique immediate So And XXXX we with will population. lives remain with a focus pneumonitis that based action improve our disease while to ILD. three believe to as related have the be such estimate other tissue clinical sales addressable utility leading anti-fibrotics chronic to including nintedanib. $X market for hypersensitivity and the We $X diseases, pirfenidone these and of range on in connective billion billion on lung unmet diseases
proof-of-concept alter So significant of pulmonary the unique pipeline Phase study Ib/IIa progression the diseases disease. we if in where to in achieve opportunity action XXXX's our expand we sarcoidosis, this mechanism of could see in related
each we activities pre-clinical collaboration the academic early While of Behring CSL pipeline. are collaboration also grant rights from for and related research to development up fourth to CSL network emerges that the development option development a CSL of this we the subsequent IND from will research from candidates for four and fund to the to candidate end announced we of research corporate advance an on the leading end, focused of with product development license derived To each with tRNA quarter, our we translational that worldwide a will institutions. and XXXX, continue all collaboration. in synthetases activities of to candidate
to into Difficulty] further earn of fees both continue pleased to $XX capabilities decision research this that us and are in to potential million validates opportunity milestones to and [Technical gives development. our early enter research partnership We option the CSL's up
new based is activities including of those new life-saving biotherapeutics looks development world-class that speed capabilities what Recognizing than long product than partnership. are in mutually with CSL's focus these global therapies, XX in of CSL Behring areas more long delivering be employs to partner, on beneficial the For rare development strategy. innovative CSL's collaborations Melbourne, of we forward element and and conditions. R&D a targeting key serious CSL's other XX,XXX during hematology, unfamiliar growth countries. and people term and our partnerships will immunology, you multiple a medical more believe new aTyr can therapies leveraging Australia therapeutics, leader that a are
in further also on be presented a the Cancer Data Annual evidence with Atlanta. immune We Medical provided of collaboration XXXX that pilot Meeting pilot poster XXXX and a up at the announced expansion study American initiation April a research Research Association for modulates Nebraska coming biology and will cell the has X from study the of of Center. University
of regulation advance Our understanding expanded seeks for to opportunities immune and additional to biology the therapeutic explore our XXXX. NRP-X responses of and collaboration
cancer for investigator this the calls. look collaboration. XXXX mechanisms on myeloid our the potentially Dr. excited Datta on of related properties groundbreaking will biology and Molecular updates anti-NRP-X metastasis. Professor modulating progression and to role cells of we Specifically, at individual the in the published and the in coreceptors as to involvement extensively and progress Dr. of research in immunology Biochemistry of field NRP-X antibodies ligands, this NRP-X domain the investigate and different functional serve impact will molecular conducts forward including of biology. cancer specific about Kaustubh and providing has of and research We're biology, Datta, the macrophage of Biology UNMC, future
appropriate yet led late I in that with myeloid interrogated inflammation in evidence few expressed just Fe, XXXX's and specifically XXXX data We cells, Phase critically resources conducted to down-regulate using multiple difficult, Santa on We XXXX. we This collaborated and weeks vitro a lung review reviews, ability consistent presented which experts conviction unique clinical justify bind ago submitted us progress demonstrating Phase application worldwide increased clinical animal at approach the approach giving for ability healthy pre-clinical and to We of XX strategic action NRP-X, advancement make safety to portfolio corporate our Ib/IIa immediate Keystone In mechanism to science pulmonary neutrophils volunteers, tough clinical innovative where decisions, us these Symposia translational as the in as trial an the pulmonary its synthetase vivo. transition trial first program execution. as the clinic. conference a through manner further to advance surface opinion, first our QX. year this evidence myeloid our IND as program We road provides did with sarcoidosis of our program, progress summary, is cells our is initial led tolerability of restructuring. Finally, advance an in in emphasize which seen systematically myeloid supported both launched readouts did of on data in This the development. into and in XXXX's models our for to the XXXX our on The further XXXX. driven leading our data successful cells, the early biology of more with portfolio. single in past decisions ascending chose transitional data stage cogent significant XXXX efficient we and establishing we This early has focused dose then We we matured data map into subsequently and XXXX in programs. XXXX to the with science efficacy a transparency we've earlier guided we not we development. to as indication look by during
an opportunities. to provides With Officer, Our novel Chief like discovery validation Broadfoot Behring recent review over turn collaboration results. to financial translational with and it I'd Financial Jill advancing to our CSL that, therapeutic potential our to important approaches to aTyr's
